NCT02835976View on ClinicalTrials.gov

A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Healthy Volunteer
Interventions
DRUG

Olesoxime

Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

collaborator

Trophos SA

UNKNOWN

NCT02835976 - A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime) | Biotech Hunter | Biotech Hunter